# Phase 2 Nervous System Diseases trials recruiting: 23 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials in phase 2 for Nervous System Diseases that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Nervous System Diseases trials: 23 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/nervous-system-diseases

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 23
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07889115 | Evaluation of the Effect of Amantadine in the Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients | Al-Azhar University | Phase 2 | Not yet recruiting | Breast Cancer, Peripheral Neuropathy Due to Chemotherapy, VAS Score | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889115) |
| September 4, 2026 | NCT07804615 | A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently... | Vima Therapeutics | Phase 2 | Recruiting | PARKINSON DISEASE (Disorder) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804615) |
| July 15, 2026 | NCT07704840 | A Pilot Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants With Post-Stroke... | Sponsor not shown (see the record) | Phase 2 | Recruiting | Post-Stroke Spasticity | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704840) |
| June 23, 2026 | NCT07662863 | Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01) | Fudan University | Phase 2 | Not yet recruiting | Bladder Cancer, Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Peripheral Neuropathy | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662863) |
| June 17, 2026 | NCT07654114 | Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome | Connecta Therapeutics, S.L. | Phase 2 | Recruiting | Fragile X Syndrome (FXS), Fragile X Syndrome | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654114) |
| May 15, 2026 | NCT07589595 | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | Eli Lilly and Company | Phase 2 | Recruiting | Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589595) |
| May 14, 2026 | NCT07587255 | Efficacy of Extracorporeal Shockwave Therapy on Plantar Fasciitis in Patients With Peripheral Neuropathy | National Taiwan University Hospital | Phase 2 | Not yet recruiting | Neuropathic Pain, Plantar Fasciitis | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07587255) |
| March 10, 2026 | NCT07459647 | A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia | MapLight Therapeutics | Phase 2 | Recruiting | Schizophrenia | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07459647) |
| January 8, 2026 | NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | Black Diamond Therapeutics, Inc. | Phase 2 | Recruiting | Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System... | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07326566) |
| December 24, 2025 | NCT07303296 | Efficacy and Safety Study of Bilateral IVT Injection of GS010 at Two Dose Levels in LHON Patients | Sponsor not shown (see the record) | Phase 2 | Recruiting | Leber Hereditary Optic Disease | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07303296) |
| October 24, 2025 | NCT07220603 | An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) | PepGen Inc | Phase 2 | Recruiting | Myotonic Dystrophy 1 | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07220603) |
| August 7, 2025 | NCT07109817 | Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer | Montefiore Medical Center | Phase 2 | Recruiting | Breast Cancer, Peripheral Neuropathy | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07109817) |
| August 6, 2025 | NCT07105709 | Open-label Extension Study in Participants With Early Alzheimer's Disease | GlaxoSmithKline | Phase 2 | Recruiting | Alzheimer's Disease | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07105709) |
| March 20, 2025 | NCT06887192 | A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis | MapLight Therapeutics | Phase 2 | Recruiting | Psychosis Associated With Alzheimer's Disease | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06887192) |
| October 21, 2024 | NCT06649747 | Safety and Efficacy Study on AFA-281 for the Treatment of Low Back Pain | Afasci Inc | Phase 2 | Not yet recruiting | Lumbosacral Radiculopathy | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06649747) |
| September 26, 2024 | NCT06614322 | SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy. | University of Rochester | Phase 2 | Recruiting | Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), Chemotherapy Induced Peripheral Neuropathy... | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06614322) |
| January 17, 2024 | NCT06208332 | The "What Is Important to Us" Communication Intervention Pilot Clinical Trial | Seattle Children's Hospital | Phase 2 | Recruiting | Critical Illness, Neurologic Disorder | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06208332) |
| October 10, 2023 | NCT06073886 | Personalized Brain Stimulation to Treat Chronic Concussive Symptoms | University of California, Los Angeles | Phase 2 | Recruiting | Post-Concussion Syndrome, Concussion, Brain, Mild Traumatic Brain Injury, Head Injury, Headache, Dizziness, Cognitive... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06073886) |
| August 25, 2023 | NCT06012552 | Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in... | Military Institute od Medicine National Research Institute | Phase 2 | Recruiting | Nervous System Diseases | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06012552) |
| October 4, 2022 | NCT05565833 | Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND) | University of Virginia | Phase 2 | Recruiting | Insomnia, Cognitive Dysfunction, Mild Cognitive Impairment, Sleep Initiation and Maintenance Disorders, Sleep... | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05565833) |
| May 20, 2022 | NCT05383742 | Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen... | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Recruiting | Tuberculous Meningitis | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05383742) |
| November 3, 2021 | NCT05104736 | PT-112 in Subjects With Thymoma and Thymic Carcinoma | National Cancer Institute (NCI) | Phase 2 | Recruiting | Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05104736) |
| July 8, 2020 | NCT04460872 | Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury | North Florida Foundation for Research and Education | Phase 2 | Recruiting | Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injury, Central Nervous System Diseases... | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04460872) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| MapLight Therapeutics | 2 |
| Vima Therapeutics | 1 |
| Connecta Therapeutics, S.L. | 1 |
| PepGen Inc | 1 |
| National Cancer Institute (NCI) | 1 |
| Military Institute od Medicine National Research Institute | 1 |
| Afasci Inc | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
| Al-Azhar University | 1 |
| Montefiore Medical Center | 1 |
| Black Diamond Therapeutics, Inc. | 1 |
| University of Virginia | 1 |
| Seattle Children's Hospital | 1 |
| University of California, Los Angeles | 1 |
| University of Rochester | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| North Florida Foundation for Research and Education | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| National Taiwan University Hospital | 1 |
| Fudan University | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 14 |
| Canada | 4 |
| South Korea | 3 |
| Spain | 2 |
| Poland | 2 |
| Argentina | 2 |
| France | 2 |
| Taiwan | 2 |
| Bulgaria | 1 |
| Chile | 1 |
| Czechia | 1 |
| Hungary | 1 |
| Italy | 1 |
| Portugal | 1 |
| Romania | 1 |
| Serbia | 1 |
| Slovakia | 1 |
| Brazil | 1 |
| India | 1 |
| Kenya | 1 |
| Malawi | 1 |
| Mexico | 1 |
| Peru | 1 |
| Philippines | 1 |
| South Africa | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Stone and masonry companies in the United States](https://specstream.ai/data/businesses/stone-and-masonry-companies/united-states)
- [Courier and delivery companies in the United States](https://specstream.ai/data/businesses/courier-and-delivery-companies/united-states)
- [Neurology practices in the United States](https://specstream.ai/data/businesses/neurology-practices/united-states)
- [Alternative medicine clinics in the United States](https://specstream.ai/data/businesses/alternative-medicine-clinics/united-states)
- [Furniture rental companies in the United States](https://specstream.ai/data/businesses/furniture-rental-companies/united-states)
- [Restaurants in the United States](https://specstream.ai/data/businesses/restaurants/united-states)
